Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.
Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, McGonigal T, Mishra S, Schlessinger S, Smith ML, Tahir SK, Leverson JD, Souers AJ, Boghaert ER, Hickson J.
Ackler S, et al. Among authors: schlessinger s.
Pharmacol Res Perspect. 2015 Oct;3(5):e00178. doi: 10.1002/prp2.178. Epub 2015 Sep 1.
Pharmacol Res Perspect. 2015.
PMID: 26516589
Free PMC article.